<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114368">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01987167</url>
  </required_header>
  <id_info>
    <org_study_id>13-330</org_study_id>
    <secondary_id>ACTHAR</secondary_id>
    <nct_id>NCT01987167</nct_id>
  </id_info>
  <brief_title>Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis</brief_title>
  <acronym>ACHTAR</acronym>
  <official_title>Potential Neuroprotection With ACTHAR Following Acute Optic Neuritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuro-Ophthalmologic Associates, PC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Questcor Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Neuro-Ophthalmologic Associates, PC</source>
  <oversight_info>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to determine the earliest structural changes in the optic nerve
      during the acute event and during the twelve months of recovery following Acthar treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Neuro-protection</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Functional with low contrast visual acuity in bothe the eye acutely affected by optic neuritis and the clinically unaffected eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preservation of retinal nerve fiber layer.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To define the objective (micron thickness, volumetric analysis) and subjective (histopathological changes) of spectral domain optical coherence tomography (SD-OCT) at the time of clinical presentation of acute optic neuritis and during 6 months of recovery following ACTHAR treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Preservation and/or restoration of electrophysiological parameters for patients with acute optic neuritis.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To define the electrophysiological changes at the onset and following an acute event of optic neuritis with Multifocal electroretinography(mERG) and visual evoked potentials (VEP)</description>
  </other_outcome>
  <other_outcome>
    <measure>Structual, Physiological and Metabolic changes during an acute event of optic neuritis</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>to determine the earliest structural, physiological, and metabolic changes in the optic nerve during an acute event of demyelinating optic neuritis and the natural history of these changes over 6 months.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>-ACHTHAR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous ACTHAR 5 days of 80 IU and 10 Days of 40 IU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACTHAR</intervention_name>
    <description>Injectable Gel</description>
    <arm_group_label>-ACHTHAR</arm_group_label>
    <other_name>Repository Corticotropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  unilateral acute demyelinating optic neuritis

          -  Able to provide informed consent

          -  age 18 or older

          -  can perform the above listed electrophysiologic diagnostic testing

          -  can perform high and low contrast visual acuity and visual field perimetry

        Exclusion Criteria:

          -  prior diagnosis of remitting/relapsing multiple sclerosis(RRMS)

          -  secondary progressive MS(SPMS)

          -  primary progressive MS (PPMS)

          -  undergoing treatment with medications approve for treatment of RRMS(except
             corticosteroids for a condition not involving central nervous system demyelination)

          -  prior diagnosis of systemic lupus erythematosis

          -  mixed connective tissue disease

          -  vasculitis

          -  sarcoidosis

          -  neuro-myelitis optica
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C Sergott, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Neuro Ophthalmologic Associates</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria C Massini, COT</last_name>
      <phone>215-825-4725</phone>
      <email>mmassini@willseye.org</email>
    </contact>
    <investigator>
      <last_name>Robert C Sergott, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark L Moster, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Esther Bisker, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tim Kim, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 12, 2013</lastchanged_date>
  <firstreceived_date>November 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute optic neuritis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
